The key risk is not product usefulness but value capture. Credo must prove that optics,
ALC and
scale-up adjacencies can clear slow
qualification gates before larger vendors bundle around it or
hyperscalers squeeze price. The balance sheet lowers financing risk, but concentration and valuation keep the equity unforgiving.